CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to ...

Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...

Shares in the brain drug developer rose by more than 20% Monday on news of the deal, which will forestall Teva's generic copy ...

Axsome Therapeutics, Inc. (NASDAQ:AXSM) signed a settlement agreement with Teva Pharmaceuticals Inc (NYSE:TEVA). The ...

With the settlement, Teva will not market the Auvelity generic until September 30, 2038, Axsome said in a Monday press ...

Teva has not raised capital since it acquired Actavis from Allergan in 2016 - a deal worth nearly $40 billion and for which ...

Pyridostigmine bromide extended-release tablets: Alvogen and Rising Pharmaceuticals have both reported shortages of pyridostigmine bromide 180-milligram, extended-release tablets. Rising estimated ...

Axsome Therapeutics, Inc.'s' stock surges 30% amid key catalysts. Learn why it's now rated a Buy wih upcoming data opportunities. Click for my AXSM update.

Shares in biopharmaceutical group Axsome Therapeutics (AXSM) surged 23% today after it said it had settled a legal dispute ...

AXSM stock rises 20% as it settles Auvelity patent litigation with Teva, protecting the drug's exclusivity in the United States at least until Sept. 30, 2038.

Axsome Therapeutics (AXSM) stock rallied 15% on news the company has settled patent litigation with Teva (TEVA) over a ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...